Fangsheng Pharmaceutical plans to acquire the marketing authorization for "Compound Acetate Dexamethasone Cream."
I'm PortAI, I can summarize articles.
Fangsheng Pharmaceutical announced that it has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream." This move aims to enrich the company's product line, promote the development strategy of innovative traditional Chinese medicine, and is expected to bring new profit growth points to the company, enhancing its market competitiveness
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments